Insider Transactions in Q3 2022 at Vertex Pharmaceuticals Inc (VRTX)
Insider Transaction List (Q3 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 19
2022
|
Jonathan Biller EVP and Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,294
+50.0%
|
-
|
|
Aug 15
2022
|
Joy Liu SVP, General Counsel |
SELL
Open market or private sale
|
Direct |
3,747
-5.22%
|
$1,135,341
$303.14 P/Share
|
|
Aug 15
2022
|
Reshma Kewalramani CEO & President |
SELL
Open market or private sale
|
Direct |
11,689
-10.5%
|
$3,565,145
$305.06 P/Share
|
|
Aug 15
2022
|
Stuart A Arbuckle EVP, COO |
SELL
Open market or private sale
|
Direct |
22,173
-6.3%
|
$6,718,419
$303.05 P/Share
|
|
Aug 15
2022
|
Stuart A Arbuckle EVP, COO |
BUY
Exercise of conversion of derivative security
|
Direct |
6,571
+8.88%
|
$1,018,505
$155.57 P/Share
|
|
Aug 10
2022
|
Joy Liu SVP, General Counsel |
SELL
Open market or private sale
|
Direct |
36
-0.27%
|
$10,800
$300.32 P/Share
|
|
Aug 10
2022
|
Stuart A Arbuckle EVP, COO |
SELL
Open market or private sale
|
Direct |
180
-0.15%
|
$54,180
$301.17 P/Share
|
|
Aug 10
2022
|
Stuart A Arbuckle EVP, COO |
BUY
Exercise of conversion of derivative security
|
Direct |
64
+0.1%
|
$9,920
$155.57 P/Share
|
|
Aug 09
2022
|
Ourania Tatsis EVP, Chief Reg. & Quality Off. |
SELL
Open market or private sale
|
Direct |
1,400
-0.6%
|
$418,600
$299.68 P/Share
|
|
Aug 09
2022
|
Joy Liu SVP, General Counsel |
SELL
Open market or private sale
|
Direct |
946
-6.6%
|
$283,800
$300.0 P/Share
|
|
Aug 09
2022
|
Stuart A Arbuckle EVP, COO |
SELL
Open market or private sale
|
Direct |
5,690
-4.32%
|
$1,707,000
$300.98 P/Share
|
|
Aug 09
2022
|
Stuart A Arbuckle EVP, COO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,926
+2.81%
|
$298,530
$155.57 P/Share
|
|
Aug 08
2022
|
Sangeeta N. Bhatia Director |
SELL
Open market or private sale
|
Direct |
621
-2.46%
|
$181,332
$292.97 P/Share
|
|
Aug 08
2022
|
David Altshuler EVP, Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,304
-0.71%
|
$380,768
$292.8 P/Share
|
|
Aug 08
2022
|
David Altshuler EVP, Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,304
+3.37%
|
$243,848
$187.53 P/Share
|
|
Aug 01
2022
|
Bastiano Sanna EVP, Cell & Genetic Therapies |
SELL
Payment of exercise price or tax liability
|
Direct |
766
-1.83%
|
$211,416
$276.62 P/Share
|
|
Jul 29
2022
|
Sangeeta N. Bhatia Director |
SELL
Open market or private sale
|
Direct |
621
-1.83%
|
$173,259
$279.58 P/Share
|
|
Jul 25
2022
|
Jeffrey M Leiden Executive Chairman |
SELL
Open market or private sale
|
Direct |
132,079
-46.74%
|
$37,114,199
$281.39 P/Share
|
|
Jul 25
2022
|
Jeffrey M Leiden Executive Chairman |
BUY
Exercise of conversion of derivative security
|
Direct |
60,342
+30.97%
|
$5,491,122
$91.05 P/Share
|
|
Jul 19
2022
|
David Altshuler EVP, Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
17,865
-9.43%
|
$5,145,120
$288.18 P/Share
|
|
Jul 19
2022
|
David Altshuler EVP, Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
17,765
+15.13%
|
$3,037,815
$171.55 P/Share
|